



Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AMRN**

Last Trade:	3.39
Trade Time:	4:15 PM ET Dec 15, 2017
Change:	0.11 (+3.354%)
Day Range	3.27 - 3.42
52-Week Range	2.81 - 4.47
Volume	2,747,033

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 14, 2017*  
[Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk](#)
- Nov 13, 2017*  
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease](#)
- Nov 13, 2017*  
[Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs](#)
- Nov 7, 2017*  
[Amarin to Present at the Jefferies London Healthcare Conference](#)
- Nov 1, 2017*  
[Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)